One-way sensitivity analysis: (A) BT versus standard therapy, (B) omalizumab versus BT.

<p>One-way sensitivity analysis: (A) BT versus standard therapy, (B) omalizumab versus BT.</p

(A) Cost-effectiveness plane; (B) Cost-effectiveness acceptability curve; and (C) Expected value of information.

<p>(A) Cost-effectiveness plane; (B) Cost-effectiveness acceptability curve; and (C) Expected value of information.</p

Sensitivity analysis for the costs of BT.

<p>Incremental cost-effectiveness ratio as a function of BT’s cost: (A) BT versus standard therapy, (B) omalizumab versus BT.</p